Zai Lab (ZLAB) Cash from Financing Activities (2018 - 2026)
Zai Lab (ZLAB) posted quarterly Cash from Financing Activities of $5.6 million for Q1 2026, down 87.08% year-on-year from $43.1 million in Q1 2025, and up 1396.05% on a QoQ basis from -$430000.0 in Q4 2025.
Zai Lab (ZLAB) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Zai Lab (ZLAB) has reported Cash from Financing Activities for 9 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.
- Quarterly Cash from Financing Activities fell 87.08% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.8 million (down 89.93% YoY) and the FY2025 annual result came in at $72.4 million, down 79.32% from the prior year.
- Cash from Financing Activities rose to $5.6 million in Q1 2026 per ZLAB's latest filing, from -$430000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for ZLAB reached as high as $237.8 million in Q4 2024 and fell as low as -$3.9 million in Q1 2023.
- A 5-year average of $24.7 million and a median of $709000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities plunged 1606.2% — and 2024, when it soared 60411.96%.
- Year by year, Cash from Financing Activities stood at -$199000.0 in 2022, then surged by 297.49% to $393000.0 in 2023, then surged by 60411.96% to $237.8 million in 2024, then plunged by 100.18% to -$430000.0 in 2025, then jumped by 1396.05% to $5.6 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $5.6 million, -$430000.0, and $20.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Zai Lab | 22.02 Bn | 22.02 Bn | 61.30 Mn | 5.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.57 Mn |
| Mar 31, 2026 | 5.57 Mn |
| Dec 31, 2025 | -430,000.00 |
| Dec 31, 2025 | -430,000.00 |
| Sep 30, 2025 | 20.79 Mn |
| Sep 30, 2025 | 20.79 Mn |
| Jun 30, 2025 | 8.85 Mn |
| Jun 30, 2025 | 8.85 Mn |
| Mar 31, 2025 | 43.14 Mn |
| Mar 31, 2025 | 43.14 Mn |
| Dec 31, 2024 | 237.81 Mn |
| Dec 31, 2024 | 237.81 Mn |
| Sep 30, 2024 | 42.21 Mn |
| Sep 30, 2024 | 42.21 Mn |
| Jun 30, 2024 | 22.32 Mn |
| Jun 30, 2024 | 22.32 Mn |
| Mar 31, 2024 | 47.55 Mn |
| Mar 31, 2024 | 47.55 Mn |
| Dec 31, 2023 | 393,000.00 |
| Dec 31, 2023 | 393,000.00 |